RE: Looking forward to this afternoon!!23 Mar 2022 10:09
A very interesting statement ....
"Dr Alex Stevenson, Chief Scientific Officer, 4D pharma, commented, "The disease control rate observed in part A of the study, at 42%, far exceeds the 10% threshold for success agreed with our partner MSD for the cohort expansion phase, boding well for the outcome of the ongoing Part B of the study. This is ground-breaking for the microbiome in immuno-oncology. Considering the advanced stage of disease of the patients in the study, end of line patients who have previously failed on a checkpoint inhibitor and have little to no remaining treatment options, these results are very promising."